KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Return on Capital Employed (2016 - 2026)

Eli Lilly filings provide 18 years of Return on Capital Employed readings, the most recent being 42.94% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed rose 806.0% to 42.94% in Q1 2026 year-over-year; TTM through Mar 2026 was 42.94%, a 806.0% increase, with the full-year FY2025 number at 48.39%, up 1075.0% from a year prior.
  • Return on Capital Employed hit 42.94% in Q1 2026 for Eli Lilly, up from 37.22% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 42.94% in Q1 2026 to a low of 20.0% in Q1 2023.
  • Median Return on Capital Employed over the past 5 years was 28.23% (2024), compared with a mean of 30.19%.
  • Biggest five-year swings in Return on Capital Employed: plummeted -575bps in 2023 and later surged 1002bps in 2025.
  • Eli Lilly's Return on Capital Employed stood at 25.64% in 2022, then rose by 19bps to 30.47% in 2023, then increased by 9bps to 33.16% in 2024, then rose by 12bps to 37.22% in 2025, then increased by 15bps to 42.94% in 2026.
  • The last three reported values for Return on Capital Employed were 42.94% (Q1 2026), 37.22% (Q4 2025), and 37.83% (Q3 2025) per Business Quant data.